Global Medical REIT (XRN)
NYSE:XRN
Top Page
Global Medical REIT
(NYSE:XRN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$34.00
â–¼(-1.19% Downside)
Action:ReiteratedDate:03/13/26
The score is held back primarily by weaker financial quality (2025 net loss, higher leverage, and frequently negative free cash flow) and bearish technical momentum. These are partly offset by a very high dividend yield and a more constructive earnings-call outlook featuring 2026 core FFO guidance and improved debt maturity runway, though with notable macro and execution risks.
Positive Factors
Steady operating cash flow
Consistent operating cash flow of roughly $70–77M provides a durable cash base for a REIT, supporting recurring dividend distributions, routine capital needs, and the ability to fund asset management activities without relying solely on capital markets in the near term.
Negative Factors
Elevated leverage and shrinking equity
Rising leverage and declining equity weaken balance sheet flexibility, increasing sensitivity to interest rate moves and earnings volatility. Higher leverage constrains acquisition capacity, raises refinancing exposure, and amplifies downside risk if property cash flows underperform.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady operating cash flow
Consistent operating cash flow of roughly $70–77M provides a durable cash base for a REIT, supporting recurring dividend distributions, routine capital needs, and the ability to fund asset management activities without relying solely on capital markets in the near term.
Read all positive factors
Global Medical REIT (XRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$509.76M
Dividend Yield10.01%
Average Volume (3M)138.80K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth2.73%
EPS Growth-131.16%
CountryUS
Employees26
SectorReal Estate
Sector Strength53
IndustryREIT - Industrial
Share Statistics
EPS (TTM)-0.55
Shares Outstanding13,234,830
10 Day Avg. Volume88,817
30 Day Avg. Volume138,804
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.92
Price to Sales (P/S)2.90
P/FCF Ratio-57.89
Enterprise Value/Market Cap2.21
Enterprise Value/Revenue7.12
Enterprise Value/Gross Profit152.07
Enterprise Value/Ebitda12.00
Forecast
1Y Price Target
$44.00Price Target Upside27.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$152.96M
Global Medical REIT Business Overview & Revenue Model
Company Description
Global Medical REIT, Inc. engages in the acquisition of purpose-built healthcare facilities and the leasing of those properties to healthcare systems and physician groups. The company was founded on March 18, 2011 and is headquartered in Bethesda,...
How the Company Makes Money
Global Medical REIT primarily makes money by acquiring healthcare real estate and leasing those properties to tenants under lease agreements. Its core revenue stream is rental income (base rent) paid by healthcare providers and operators that occu...
Global Medical REIT Key Performance Indicators (KPIs)
Global Medical REIT Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call presented a balanced but constructive tone: management outlined clear strategic initiatives (portfolio review, leadership appointment, disciplined capital recycling, and diversification into senior housing) and provided concrete near-term metrics and guidance. Operational performance showed strength with same-store NOI expansion and reduced leverage, and the company secured liquidity runway with no debt maturities before 2028. Notable risks remain — a challenging medical office macro environment, short-term EBIT/FFO headwinds from balance sheet actions ($0.36 of guidance impact), potential earnings dilution during disposition/redevelopment timing, and execution/operational risks as Chiron enters senior housing. Overall, positives (measurable financial improvements, strategic clarity, new investment pipeline) outweigh the manageable challenges described by management.Positive Updates
FFO and Core FFO Results
NAREIT-defined FFO per share and unit of $0.97 for the quarter; Core FFO (previously AFFO) of $1.16 per share and unit.
Negative Updates
Medical Office Sector Headwinds
Management acknowledged a prolonged bear market for medical office driven largely by higher interest rates; they expect a possible new normal of ~4% 10-year Treasury and modest rent growth of 2%–3%, which can be sub-inflationary.
Read all updates
Q4-2025 Updates
Positive
Negative
FFO and Core FFO Results
NAREIT-defined FFO per share and unit of $0.97 for the quarter; Core FFO (previously AFFO) of $1.16 per share and unit.
Read all positive updates
Company Guidance
Chiron set initial 2026 core FFO guidance of $4.30–$4.45 per share/unit (including an estimated $0.36 headwind from prior-year balance‑sheet fortification and excluding any speculative M&A), after reporting Q4 NAREIT‑defined FFO of $0.97 and quarter‑level core FFO of $1.16 per share/unit; net debt to adjusted EBITDA (REIT) was 6.2x (down 0.7x), same‑store cash NOI rose 5.4% year‑over‑year and 2.9% sequentially, and the company now has no debt maturing before 2028. The board approved a switch to a monthly dividend with the annual rate unchanged at $3.00 per share, and management said it has identified roughly $250 million of prospective dispositions, sold an early‑vintage MOB for $10 million (using proceeds to repurchase stock in a leverage‑neutral manner), and holds a 49% interest in an active‑adult development expected to deliver in 2027 with a stabilized double‑digit unlevered IRR.Global Medical REIT Financial Statement Overview
Summary
Income Statement
53
Neutral
Balance Sheet
48
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 161.03M | 138.41M | 140.93M | 137.17M | 115.80M |
| Gross Profit | 10.32M | 109.16M | 112.85M | 111.98M | 100.32M |
| EBITDA | 83.91M | 91.47M | 111.64M | 102.89M | 85.35M |
| Net Income | -5.84M | 6.63M | 20.61M | 19.14M | 17.62M |
Balance Sheet | |||||
| Total Assets | 1.24B | 1.26B | 1.27B | 1.39B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 12.45M | 6.82M | 1.28M | 4.02M | 7.21M |
| Total Debt | 663.74M | 653.59M | 624.19M | 704.65M | 579.86M |
| Total Liabilities | 712.40M | 700.57M | 661.89M | 744.20M | 625.91M |
| Stockholders Equity | 509.77M | 534.13M | 583.58M | 632.98M | 622.78M |
Cash Flow | |||||
| Free Cash Flow | -8.08M | -25.07M | 58.39M | -79.66M | -132.69M |
| Operating Cash Flow | 73.61M | 70.05M | 68.44M | 76.54M | 68.97M |
| Investing Cash Flow | -60.40M | -45.94M | 67.62M | -137.25M | -194.66M |
| Financing Cash Flow | -10.26M | -21.89M | -143.79M | 62.41M | 127.70M |
Global Medical REIT Technical Analysis
Positive
34.41
Price Trends
34.78
Negative
34.07
Positive
33.42
Positive
Market Momentum
-0.37
Negative
53.63
Neutral
81.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRN, the sentiment is Positive. The current price of 34.41 is above the 20-day moving average (MA) of 33.55, below the 50-day MA of 34.78, and above the 200-day MA of 33.42, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 53.63 is Neutral, neither overbought nor oversold. The STOCH value of 81.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XRN.
Global Medical REIT Risk Analysis
Global Medical REIT disclosed 63 risk factors in its most recent earnings report. Global Medical REIT reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Global Medical REIT Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.36B | 38.71 | 2.44% | 6.98% | 3.74% | 77.82% | |
66 Neutral | $485.72M | 86.44 | 1.16% | 12.08% | 3.40% | -240.85% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
64 Neutral | $595.22M | 30.78 | 10.87% | 7.51% | 0.68% | -1.34% | |
64 Neutral | $176.86M | 21.52 | 49.30% | 4.62% | 29.76% | 22.76% | |
54 Neutral | $1.77B | -4.08 | -15.98% | 0.80% | 4.10% | 8.96% | |
49 Neutral | $509.76M | -80.15 | -1.16% | 10.01% | 2.73% | -131.16% |
* Real Estate Sector Average
XRN
Global Medical REIT
35.44
2.89
8.88%
DHC
Diversified Healthcare Trust
7.29
5.21
249.64%
CHCT
Community Healthcare
17.00
3.49
25.86%
UHT
Universal Health Realty Income
42.90
8.37
24.23%
STRW
Strawberry Fields REIT Inc
13.22
2.84
27.41%
SILA
Sila Realty Trust, Inc.
24.60
0.85
3.59%
Global Medical REIT Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Global Medical REIT Expands Equity and Preferred Stock Programs
Positive
Mar 13, 2026
On March 11, 2026, Chiron Real Estate Inc. filed supplementary charter documents in Maryland to classify an additional 3,000,000 shares as 8.00% Series B Cumulative Redeemable Preferred Stock, lifting its total authorization to 5,300,000 preferred...
Business Operations and StrategyPrivate Placements and Financing
Global Medical REIT Establishes New Uncommitted Senior Note Facility
Positive
Mar 3, 2026
On March 2, 2026, Chiron Real Estate LP and its guarantor Chiron Real Estate Inc. entered into a Master Note and Guaranty Agreement with NYL Investors LLC and New York Life affiliates, creating an uncommitted senior note facility of up to $150 mil...
Business Operations and StrategyStock BuybackDelistings and Listing ChangesDividendsFinancial DisclosuresLegal ProceedingsPrivate Placements and Financing
Chiron Unveils Rebrand, Dividend Shift and 2026 Strategy
Positive
Feb 25, 2026
Chiron Real Estate Inc., previously known as Global Medical REIT Inc., has completed a corporate rebrand effective February 23, 2026, including a legal name change for both the company and its operating partnership, new NYSE trading symbols, and t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.